enGene Therapeutics Inc. SEC filings ENGNW
enGene Therapeutics Inc. has 267 filings in SEC EDGAR's recent list, going back to Jun 14, 2023. Its latest annual report, Form ARS, was filed on May 8, 2026 for the period ended Oct 31, 2025. The latest quarterly report (Form 10-Q) was filed on Sep 8, 2026, covering the quarter ended Jul 31, 2026. The most recent current report (Form 8-K) was filed on Sep 8, 2026 (results of operations). The company's fiscal year ends on October 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Mar 2, 2026 | — |
| CORRESP | Letter to the SEC | Feb 26, 2026 | — |
| UPLOAD | Letter from the SEC | Feb 25, 2026 | — |
| EFFECT | Filing | Nov 21, 2024 | — |
| EFFECT | Filing | Nov 21, 2024 | — |
| CORRESP | Letter to the SEC | Nov 19, 2024 | — |
| CORRESP | Letter to the SEC | Nov 19, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 18, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 18, 2024 | — |
| EFFECT | Filing | Mar 5, 2024 | — |
| CORRESP | Letter to the SEC | Mar 4, 2024 | — |
| CORRESP | Letter to the SEC | Feb 26, 2024 | — |
| CORRESP | Letter to the SEC | Jan 11, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 26, 2023 | — |
| CORRESP | Letter to the SEC | Dec 15, 2023 | — |
| UPLOAD | Letter from the SEC | Dec 8, 2023 | — |
| CERT | Filing | Oct 31, 2023 | — |
| 8-A12B | Filing | Oct 31, 2023 | — |
| 425 | Filing | Oct 24, 2023 | — |
| SEC STAFF LETTER | Filing | Sep 29, 2023 | — |
| EFFECT | Filing | Sep 29, 2023 | — |
| CORRESP | Letter to the SEC | Sep 28, 2023 | — |
| CORRESP | Letter to the SEC | Sep 25, 2023 | — |
| 425 | Filing | Sep 15, 2023 | — |
| UPLOAD | Letter from the SEC | Sep 11, 2023 | — |
| CORRESP | Letter to the SEC | Aug 29, 2023 | — |
| SEC STAFF LETTER | Filing | Aug 22, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 22, 2023 | — |
| CORRESP | Letter to the SEC | Aug 9, 2023 | — |
| UPLOAD | Letter from the SEC | Jul 12, 2023 | — |
| DRS | Filing | Jun 14, 2023 | — |
Showing 31 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ENGN (Nasdaq), ENGNW (Nasdaq)
- Fiscal year ends
- October 31
- Incorporated in
- Canada (Federal Level)
- Headquarters
- Saint-Laurent
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1980845
- Former names
- enGene Holdings Inc. (until Mar 9, 2026)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.